re Italian study

[Guest guest]

Something must have been lost in someone's translation about the CKit

study,

because according the abstract of the article in Blood, this is about

AML not CLL:

Distinct forms of tyrosine kinase domain (TKD), juxtamembrane domain,

exon 8, and internal tandem duplication (ITD) mutations of c-KIT ,

were observed in about 46% of core binding factor leukemia (CBFL)

patients. To evaluate their prognostic significance, 67 adult CBFL

patients were analysed to ascertain the c-KIT mutation status. In AML

with t(8;21), the presence of c-KIT TKD mutation at codon 816

(TKD816) was associated with a high white blood cell count at

diagnosis (median 29.60x109/L) and a higher incidence (33%) of

extramedullary leukaemia (EML) during the course of the disease. Data

also showed that the TKD816 mutation patients (n = 12) had a

significantly higher incidence of relapse and a lower overall

survival (OS) at 24 months, compared with the 17 c-KIT unmutated (c-

KIT-) patients (90% vs 35.3%, p = 0.002; 25% vs 76.5%, p = 0.006,

respectively). No difference in relapse incidence (p = 0.126) and OS

(p = 0.474) was observed between the c-KIT mutated other than TKD816

(n = 7) and the c-KIT- patients. These findings indicate that c-KIT

TKD816 mutation has a negative impact on the outcome of AML with t

(8;21).